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We concluded that although the sickling test was not highly 
sensitive, it was more sensitive than solubility and the peripheral 
blood film method.
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Approval of chronic medication
To the Editor: In response to Professor Rayner’s letter to the SAMJ,1 
I would like to point out that Discovery Health was able to resolve 
the case before it was published in your journal. Professor Rayner has 
indicated to us in writing that he would have withdrawn his letter to 
you, had it not been too late to do so.
Discovery Health formulates its funding policies using evidence-
based medicine and in consultation with South Africa’s various 
professional specialist societies and leadership. In the case of diabetes 
mellitus, current SEMDSA guidelines (published in 2009) do not 
recommend the use of HbA1c for diagnosis. We are aware of the 
American Diabetes Association statement referred to by Professor 
Rayner, which recommends the use of HbA1c as a diagnostic test. 
This continues to be debated in national forums, and in fact the 
most recent SEMDSA guidelines released in August 2010 reaffirm 
the position that HbA1c should not be used alone as a diagnostic 
criterion for diabetes or pre-diabetes.
We recognise that individual cases do sometimes merit exceptional 
decisions on clinical grounds. The doctors we employ, some of whom 
are referred to in Professor Rayner’s letter, have the challenging task 
of applying our funding policies in a way that is fair and consistent, 
taking into account both the best interests of individual patients and 
our membership base as a whole. They do so with great care. In this 
specific case, we failed to recognise up front that a clinical exception 
could have been made. Going forward we will endeavour to further 
enhance this aspect of our service.
The sustainability of our members’ medical scheme benefits 
depends on our ability to responsibly apply the principles of evidence-
based medicine wherever possible. We will always actively engage 
with the health care profession and the various representative 
societies to ensure that our funding decisions are clinically sound, 
but as noted above, there are often complex cases in ‘grey areas’ and 
we acknowledge that we do and will make errors in some of these 
situations. We always try to correct these as quickly as possible, and 
we appreciate the feedback we receive, which assists in improving our 
overall approach. We call on all health care professionals to work with 
us in a spirit of co-operation, rather than conflict. Finding the balance 
between what is best for each patient and for our private health care 
system as a whole is a complex task, and needs an active partnership 
between responsible funders and practitioners. 
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